TGFB1 and cholangiocarcinoma: In conclusion, our findings suggest that heteronemin may activate a novel signaling pathway to inhibit the expression of TGF-β, SMAD, and their signaling pathway in order to suppress the proliferation, invasion, and adhesion of cholangiocarcinoma.